Intra-arterial Albumin Infusion After Endovascular Therapy for Stroke Patients

Phase 1 Completed 57 enrolled Tianjin Huanhu Hospital

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the safety and feasibility of intra-arterial albumin infusion for patients with acute ischemic stroke after successful thrombectomy and to further explore the optimal dose of albumin through the implementation of a 3 + 3 dose-escalation design. At the maximum safe dose determined in the 3+3 dose-escalation phase, an additional 15 to 20 patients will be enrolled in the study, and comparisons were made with external patients who received endovascular treatment alone.

Timeline

Start: 2023-08-01
Primary completion: 2024-06-29
Completion: 2024-10-01

Publications

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Albumin	Protein / enzyme biologic	0.25 g/kg	Other
Subject	Albumin	Protein / enzyme biologic	0.35 g/kg	Other
Subject	Albumin	Protein / enzyme biologic	0.4 g/kg	Other
Subject	Albumin	Protein / enzyme biologic	0.45 g/kg	Other
Subject	Albumin	Protein / enzyme biologic	0.5 g/kg	Other
Subject	Albumin	Protein / enzyme biologic	0.55 g/kg	Other
Subject	Albumin	Protein / enzyme biologic	0.6 g/kg	Other

Intra-arterial Albumin Infusion After Endovascular Therapy for Stroke Patients

Summary

Timeline

Publications

Drugs

Indications